Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia

J Allergy Clin Immunol Pract. 2019 Mar;7(3):1049-1051. doi: 10.1016/j.jaip.2018.10.010. Epub 2018 Oct 17.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • 2-Naphthylamine
  • Administration, Oral
  • Adult
  • Agammaglobulinemia / blood
  • Agammaglobulinemia / drug therapy*
  • Agammaglobulinemia / virology
  • Anilides / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Carbamates / therapeutic use
  • Cyclopropanes
  • Genetic Diseases, X-Linked / blood
  • Genetic Diseases, X-Linked / drug therapy*
  • Genetic Diseases, X-Linked / virology
  • Hepacivirus
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Imidazoles / therapeutic use
  • Immunoglobulin G / blood
  • Immunoglobulins, Intravenous / therapeutic use
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / therapeutic use
  • Middle Aged
  • Proline / analogs & derivatives
  • Pyrrolidines
  • Ritonavir / therapeutic use
  • Sofosbuvir / therapeutic use
  • Sulfonamides / therapeutic use
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Valine / analogs & derivatives

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Imidazoles
  • Immunoglobulin G
  • Immunoglobulins, Intravenous
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Pyrrolidines
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • daclatasvir
  • Ritonavir
  • paritaprevir
  • Sofosbuvir

Supplementary concepts

  • Bruton type agammaglobulinemia